ライフサイエンスコーパス: foramen ovale

1 ntrast transcranial doppler to detect patent foramen ovale.

2 enosus, in both venae cavae, and through the foramen ovale.

3 the stent was successfully positioned in the foramen ovale.

4 cell stent was positioned in an unrestricted foramen ovale.

5 dical therapy alone or closure of the patent foramen ovale.

6 ations or percutaneous closure of the patent foramen ovale.

7 sient ischemic attack (TIA) and had a patent foramen ovale.

8 ited to pulmonary artery stenosis and patent foramen ovale.

9 paradoxical embolism due to existing patent foramen ovale.

10 Of 11 patients, 5 (45%) had a patent foramen ovale; 1 of these also had a primary lung carcin

11 (0, 160); umbilical vein, 134 (62, 206); and foramen ovale, 135 (37, 233).

12 16 (0, 34); umbilical vein, 29 (11, 47); and foramen ovale, 29 (7, 51).

13 (TAA), 88% had left-to-right flow across the foramen ovale, 91% had monophasic mitral inflow, and 94%

14 Patent foramen ovale, alone or together with ASA, was not assoc

15 The prevalence of patent foramen ovale among patients with cryptogenic stroke is

16 The association of patent foramen ovale and atrial septal aneurysm with stroke is

17 Patients with a patent foramen ovale and ischemic stroke, transient ischemic at

18 Patent foramen ovale and pulmonary arteriovenous shunts are ass

19 aphy identified three patients with a patent foramen ovale and right-to-left shunt flow while breathi

20 d in 47% (including 17% with isolated patent foramen ovale), and 11% had undetermined stroke etiology

21 patients had simultaneous closure of patent foramen ovale, and 19 patients had other various cardiac

22 (RAP) score (comprising the tricuspid valve, foramen ovale, and ductus venosus Doppler).

23 persistent pulmonary hypertension, a patent foramen ovale, and free-floating right-heart thrombus ar

24 ion of the inferior vena cava, right atrium, foramen ovale, and left atrium with a guidewire and 1.8F

25 ccult paroxysmal atrial fibrillation, patent foramen ovale, aortic arch atherosclerosis, atrial cardi

26 cryptogenic embolism in patients with patent foramen ovale are administration of antithrombotic medic

27 e closure (9 secundum ASDs and 4 with patent foramen ovale associated with a cerebral vascular accide

28 Foramen ovale blood flow (QFO = LVCO-QP) was estimated.

29 has been reported in patients with a patent foramen ovale, carcinoid tumor of the lung, and active c

30 results using these tools to perform patent foramen ovale closure are described.

31 in 4 and repair in 2, CABG in 2, and patent foramen ovale closure in 5.

32 pparent increased risk for concurrent patent foramen ovale closure or mitral or tricuspid repair.

33 alysis demonstrated that simultaneous patent foramen ovale closure was not associated with an increas

34 h cryptogenic stroke or TIA who had a patent foramen ovale, closure with a device did not offer a gre

35 a demonstration of both technologies, patent foramen ovale creation and closure was performed in a sw

36 mainly the adult population, such as patent foramen ovale device closure and closure of postinfarct

37 f the ten patients undergoing semi-invasive (foramen ovale) electrode monitoring reveals that for at

38 ients, all of whom underwent recordings with foramen ovale electrodes and scalp electroencephalogram.

39 mesial temporal activity using intracranial foramen ovale electrodes in two patients with Alzheimer'

40 Closure of a patent foramen ovale for secondary prevention of cryptogenic em

41 One possible exception is patent foramen ovale, for which high-risk features may warrant

42 Patent foramen ovale has been associated with increased risk of

43 lowed by ostium secundum ASD in 6 and patent foramen ovale in 4.

44 benefit associated with closure of a patent foramen ovale in adults who had had a cryptogenic ischem

45 The Patent foramen ovale In Cryptogenic Stroke Study (PICSS) evalua

46 th warfarin or aspirin as part of the Patent Foramen Ovale in Cryptogenic Stroke Study (PICSS), based

47 hocardiograms in 11 patients showed a patent foramen ovale in one patient but no systemic source of e

48 that occur in the major veins and across the foramen ovale in the circulation of the fetal lamb.

49 en pulmonary embolism coexists with a patent foramen ovale, increased pressure in the right atrium ma

50 Whether closure of a patent foramen ovale is effective in the prevention of recurren

51 e of percutaneous closure devices for patent foramen ovale is reviewed.

52 d paradoxical emboli in patients with patent foramen ovale is unknown.

53 Transcatheter closure of patent foramen ovale may prevent a substantial proportion of cr

54 rmal LV length, reversed flow in the TAA and foramen ovale, monophasic mitral inflow, and LV dysfunct

55 m-type atrial septal defect (n=12) or patent foramen ovale (n=5) by a totally endoscopic approach, ut

56 e (11%), aortic valve procedure (9%), patent foramen ovale or atrial septal defect closure (23%), car

57 ing of intracranial atheroma, patent cardiac foramen ovale, or elevated levels of antiphospholipid an

58 re of secundum atrial septal defects, patent foramen ovale, patent ductus arteriosus, stent placement

59 ients 18 to 60 years of age who had a patent foramen ovale (PFO) and had had a cryptogenic ischemic s

60 A causal relationship between patent foramen ovale (PFO) and migraine has been hypothesized,

61 evention of embolism in patients with patent foramen ovale (PFO) and otherwise unexplained ischemic s

62 ischemic attack presumably related to patent foramen ovale (PFO) are at risk for recurrent cerebrovas

63 The role of a patent foramen ovale (PFO) as a risk factor for ischemic stroke

64 Patent foramen ovale (PFO) can be detected in up to 43% of pati

65 -documented, those for catheter-based patent foramen ovale (PFO) closure are still evolving.

66 patients who underwent transcatheter patent foramen ovale (PFO) closure for paradoxical embolism.

67 Percutaneous transcatheter patent foramen ovale (PFO) closure is now standard practice and

68 Trials of patent foramen ovale (PFO) closure to prevent recurrent stroke

69 The role of surgical closure of patent foramen ovale (PFO) for cerebral infarction (CI) or tran

70 close atrial septal defects (ASD) and patent foramen ovale (PFO) has a number of limitations, includi

71 Patent foramen ovale (PFO) has been associated with migraine, b

72 ss the risk of ischemic stroke from a patent foramen ovale (PFO) in the multiethnic prospective cohor

73 The efficacy of closure of a patent foramen ovale (PFO) in the prevention of recurrent strok

74 The patent foramen ovale (PFO) is a normal interatrial communicatio

75 Patent foramen ovale (PFO) is associated with cryptogenic strok

76 Patent foramen ovale (PFO) is associated with stroke, but there

77 Patent foramen ovale (PFO) is experiencing increased clinical i

78 Patent foramen ovale (PFO) is implicated in platypnea-orthodeox

79 Patent foramen ovale (PFO) is prevalent in patients with migrai

80 Percutaneous transcatheter closure of patent foramen ovale (PFO) is used as an alternative to surgery

81 A patent foramen ovale (PFO) may permit arterial embolization of

82 ectiveness of percutaneous closure of patent foramen ovale (PFO) plus medical therapy versus medical

83 Patent foramen ovale (PFO) was detected with contrast injection

84 -to-left shunted blood flow through a patent foramen ovale (PFO) would not be cooled.

85 with atrial septal aneurysm (SA) and patent foramen ovale (PFO), and to determine the efficacy of me

86 to determine the association between patent foramen ovale (PFO), atrial septal aneurysm (ASA), and s

87 headache symptoms in patients with a patent foramen ovale (PFO), both of which conditions are highly

88 to evaluate the relationship between patent foramen ovale (PFO), ischemic stroke, and subclinical ce

89 Controversy surrounds the issue of patent foramen ovale (PFO), stroke, and secondary prevention st

90 res to repair incidentally discovered patent foramen ovale (PFO).

91 ulting in a right-to-left shunt via a patent foramen ovale (PFO).

92 utility in quantitative assessment of patent foramen ovales (PFO).

93 Patent foramen ovales (PFOs) are common congenital cardiac defe

94 Whether closure of a patent foramen ovale reduces the risk of recurrence of ischemic

95 diseases causing stroke, the role of patent foramen ovale remains controversial.

96 A strong inverse relationship between foramen ovale shunt and pulmonary blood flow was noted (

97 The wide range we found in foramen ovale shunting suggests a degree of variability

98 closure of an atrial septal defect or patent foramen ovale to assess how the procedure affected migra

99 sus stream preferentially passed through the foramen ovale to the left atrium.

100 ifty-four (86%) had effective closure of the foramen ovale (trivial or no residual shunt by echocardi

101 Patent foramen ovales vary in both anatomical and functional si

102 Foramen ovale volume blood flow (left ventricular cardia

103 <.001), and DA volume blood flow (P<.01) and foramen ovale volume blood flow (P<.03) decreased.

104 cept for 19.6 +/- 2.3% of the cycle when the foramen ovale was closed during atrial contraction.

105 In the second group, the patent foramen ovale was not successfully created in 1 animal,

106 of medical therapy (895 patients) for patent foramen ovale were included.

107 theter closure or medical therapy for patent foramen ovale were required to include at least 10 patie

108 All patent foramen ovales were completely closed in the first group

109 Here, we report stenting of the foramen ovale with a large, open-cell stent via percutan

110 ly assigned to undergo closure of the patent foramen ovale with the Amplatzer PFO Occluder or to rece